ConductScience.org, home

Paper42898005PubMed

Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.

Rosenberg A and 9 others. Eur J Neurol, 2026.

Cite this record

ConductScience Library. Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics. Papers, record 42898005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42898005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.
Journal
Eur J Neurol
Year
2026
Publication types
Journal Article, Multicenter Study
Revised in PubMed
2026-10-22

Source PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rosenberg AAnnahttps://orcid.org/0000-0003-1456-7991
2Rennie AAnnahttps://orcid.org/0000-0002-0976-8062
3Ekman UUrbanhttps://orcid.org/0000-0003-3926-8656
4Daniilidou MMakrinahttps://orcid.org/0000-0002-5460-9802
5Hall AAnette
6Matton AAnnahttps://orcid.org/0000-0002-7819-0495
7Solomon AAri
8Wahlund LOLars-Olof
9Kivipelto MMiia
10Westman EErichttps://orcid.org/0000-0002-3115-2977

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Alzheimer DiseaseMajor topic
Amyloid beta-PeptidesMajor topic
Cognitive DysfunctionMajor topic
Eligibility DeterminationMajor topic
Humans
Sweden
Female
Male
Aged
Aged, 80 and over
Cohort Studies

Source PubMed

Download CSV of topics

Grants11

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
101112145Innovative Health InitiativePubMed
101132933Innovative Health InitiativePubMed
Region Stockholm (ALF)PubMed
FoUI-104172Center for Innovative MedicinePubMed
357810EU Joint Programme - Neurodegenerative Disease ResearchPubMed
AF-1031812AlzheimerfondenPubMed
2025-02405VetenskapsrådetPubMed
Konung Gustaf V:s och Drottning Victorias FrimurarestiftelsePubMed
FO2026-0228HjärnfondenPubMed
2025-02071Forskningsrådet om Hälsa, Arbetsliv och VälfärdPubMed
2025-03749VINNOVAPubMed

Source PubMed

Download CSV of grants

References41

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
141957377Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer's disease continuum.Nat Commun2026https://conductscience.org/library/papers/41957377PubMed
240155270Donanemab: Appropriate use recommendations.J Prev Alzheimers Dis2025https://conductscience.org/library/papers/40155270PubMed
337481563Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis.Alzheimers Res Ther2023https://conductscience.org/library/papers/37481563PubMed
441732200Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline.Lancet Reg Health Eur2026https://conductscience.org/library/papers/41732200PubMed
538862265Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.J Neurol Neurosurg Psychiatry2024https://conductscience.org/library/papers/38862265PubMed
640058984Developing Treatment Models for the Delivery of the Antiamyloid Therapy, Lecanemab: Considerations for Implementation of Lecanemab in Healthcare Systems.Am J Geriatr Psychiatry2025https://conductscience.org/library/papers/40058984PubMed
79058064Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging.Eur Neurol1997https://conductscience.org/library/papers/9058064PubMed
837459141Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.JAMA2023https://conductscience.org/library/papers/37459141PubMed
938593394Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study.Neurology2024https://conductscience.org/library/papers/38593394PubMed
1040997839Treatment for Alzheimer's disease.Lancet2025https://conductscience.org/library/papers/40997839PubMed
1140011174Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease.J Prev Alzheimers Dis2025https://conductscience.org/library/papers/40011174PubMed
1239308280Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population.BJPsych Open2024https://conductscience.org/library/papers/39308280PubMed
1332138686The MemClin project: a prospective multi memory clinics study targeting early stages of cognitive impairment.BMC Geriatr2020https://conductscience.org/library/papers/32138686PubMed
1441225766Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations.Alzheimers Dement2025https://conductscience.org/library/papers/41225766PubMed
1541544372Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic.J Prev Alzheimers Dis2026https://conductscience.org/library/papers/41544372PubMed
161431963Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.J Neurol Neurosurg Psychiatry1992https://conductscience.org/library/papers/1431963PubMed
1737357274Editorial: Lecanemab: Appropriate Use Recommendations - A Commentary from a European Perspective.J Prev Alzheimers Dis2023https://conductscience.org/library/papers/37357274PubMed
1829653606NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Alzheimers Dement2018https://conductscience.org/library/papers/29653606PubMed
1937586881Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.Neurology2023https://conductscience.org/library/papers/37586881PubMed
2036130840β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.Neurology2022https://conductscience.org/library/papers/36130840PubMed

See all 41 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42898005

GET https://conductscience.org/api/papers/v1/42898005/references?page=2